Collagenase Clostridium histolyticum (Endo/SOBI/Asahi Kasei)

N/A

Report date: 2026/03/28 20:00:32

Base Information

Drug NameCollagenase Clostridium histolyticum (Endo/SOBI/Asahi Kasei)
Drug Alias Namecollagenase clostridium histolyticum-aaes胶原酶梭菌溶组织梭菌胶原酶XiapexCordase +[12] 
ClassificationNatural product/Extract > Microbial extractBiologics
Mechanisms of ActionCollagenase replacementsCollagen inhibitors
TargetsCollagen
Therapy Area/IndicationsCelluliteUlcerFoot Ulcer +[15] 
Global Approved IndicationsDupuytren Contracture
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2010/02/02
Country/TerritoryCanadaUnited StatesSweden +[16] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBiospecifics
China Registration ClassN/A

Develop Information

Active CompaniesEndo Global Biologics LtdKeenova Therapeutics plcAuxilium Pharmaceuticals Inc +[6] 
Inactive CompaniesAdvance Biofactures CorporationAzidus BrasilPfizer Inc +[7] 
Active IndicationsCelluliteCutis LaxaPenile Induration +[10] 
Inactive IndicationsUlcerFoot UlcerDiabetic Foot +[5] 

Other Information

ATC CodeM09AB02
Related LinksN/A